Anorexia nervosa

Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
Mercoledì, Maggio 8, 2024
FDA, Research, PTSD, MD, Depression, Webcast, TRD, Mental health, Patient, Pivotal, DSM-IV codes, Gold, Anorexia nervosa, Drug development, Therapy, CMPS, Pharmaceutical industry

Second quarter 2024 net cash used in operating activities is expected to be in the range of $32 million to $38 million.

Key Points: 
  • Second quarter 2024 net cash used in operating activities is expected to be in the range of $32 million to $38 million.
  • The Compass Pathways management team will host a conference call at 8:00am ET (1:00pm UK) on May 8, 2024.
  • A live webcast of the call will be available on Compass Pathway’s website at: First Quarter 2024 Financial Results .
  • The call will also be webcast on the Compass Pathways website and archived for 30 days.

New US product, ORMALVI™ (dichlorphenamide) tablets, launches for Primary Periodic Paralysis (PPP) treatment

Retrieved on: 
Mercoledì, Maggio 8, 2024
FDA, General Health, Pharmaceutical, Health, Fetus, Cardiomyopathy, Torrent, Acidosis, Respiratory acidosis, Full, Diclofenamide, Risk, Pregnancy, Cognitive disorder, Milk, Aspirin, Metabolic acidosis, Dysgeusia, Hyperkalemia, Aplastic anemia, Partnership, PPP, Agranulocytosis, Anorexia nervosa, Human, Carbonic anhydrase inhibitor, SVP, Tablet, Incidence, Patient, Nursing, Lethargy, Serum, Hyperkalemic periodic paralysis, Diagnosis, Myopathy, Hypokalemic periodic paralysis, Paralysis, Paresthesia, Cycle, Stevens–Johnson syndrome, Hypokalemia, Quality of life, Argyreia nervosa, Sulfonamide, Coma, Pharmaceutical industry

We want to provide them with the support that they require to effectively manage their PPP.

Key Points: 
  • We want to provide them with the support that they require to effectively manage their PPP.
  • ORMALVI™ is an oral carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.
  • Simply Stated: Research Updates in Periodic Paralysis - Quest | Muscular Dystrophy Association [online] Available at: https://mdaquest.org/simply-stated-research-updates-in-periodic-paralysis Accessed 23 Nov. 2023.
  • The impact of permanent muscle weakness on quality of life in periodic paralysis: a survey of 66 patients.

Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center

Retrieved on: 
Mercoledì, Novembre 15, 2023
Psilocybin, COMP, Depression, Safety, CMPS, Psychology, Maudsley Hospital, Mental health, Maudsley, Psychiatrist, NIHR, Trial of the century, TRD, Partnership, Anorexia nervosa, Suicide, Lead, Nursing, Pharmaceutical industry, Compass, Research, Innovation

The ongoing phase 3 program is the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted and follows promising results from Compass’s phase 2b study of COMP360 psilocybin treatment.

Key Points: 
  • The ongoing phase 3 program is the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted and follows promising results from Compass’s phase 2b study of COMP360 psilocybin treatment.
  • The phase 3 program consists of two pivotal trials (COMP 005 and COMP 006), and each trial has an integrated, long-term outcomes component.
  • COMP 006 will take place in the UK and globally and will study three dose arms of COMP360 (25mg, 10mg and 1mg).
  • COMP 005 is a US-based trial examining the effect of a single 25mg dose of COMP360 psilocybin, compared with placebo.

atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights

Retrieved on: 
Martedì, Novembre 14, 2023
Sale, Acquisition, Safety, Pivotal, EGX, DMT, Entrepreneurship, Aes, Plasma, MDMA, Investment, Exercise, CIAS, Administration, Patient, QT, Research, Cognition, American College, G&A, Pharmacology, OTF, Permeability, Drug discovery, IB, TRD, PTSD, OUD, R, Neuroscience, Research and development, Mental health, AI, Poster, Taste, Pharmaceutical industry, Bank, Medicinal plants, Rare-earth element, Vaccine, Medical device, Psychopharmacology, Anorexia nervosa, Ibogaine

NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported third quarter 2023 financial results and provided corporate updates.

Key Points: 
  • NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported third quarter 2023 financial results and provided corporate updates.
  • The on-going Phase 2b study will evaluate 20mg and 40mg of RL-007 vs. placebo in patients with CIAS, with topline results expected in 2H 2024.
  • The poster will be presented at the American College of Neuropsychopharmacology (ACNP) annual meeting on Dec 5, 2023, 5:00 – 7:00 PM ET.
  • In November 2023, atai acquired all remaining outstanding shares of its subsidiary, DemeRx IB, Inc.

Monte Nido & Affiliates Expands Eating Disorder Treatment with New Day Treatment Location in Houston

Retrieved on: 
Lunedì, Dicembre 4, 2023
Motivation, Argyreia nervosa, Research, Depression, Prevalence, ARFID, Intensive outpatient program, CPT, IOP, PHP, OSFED, Eating, Eating disorder, Network affiliate, Trauma, PTSD, Anorexia nervosa, Doctor of Philosophy, LMHC, Psychiatry, Helsinki University Central Hospital, Binge eating disorder, Health insurance, Nursing

HOUSTON, Dec. 4, 2023 /PRNewswire/ -- Monte Nido & Affiliates, one of the leading eating disorder treatment providers in the country, today announces a new day treatment program, Monte Nido Houston Eating Disorder Day Treatment. Located in the Memorial City area of Houston, this program provides eating disorder treatment for adolescents and adults of all genders and complements the company's two residential programs by allowing clients to transition from 24/7 care to outpatient therapy, which is proven to support lasting recovery.

Key Points: 
  • HOUSTON, Dec. 4, 2023 /PRNewswire/ -- Monte Nido & Affiliates , one of the leading eating disorder treatment providers in the country, today announces a new day treatment program, Monte Nido Houston Eating Disorder Day Treatment .
  • Monte Nido Houston Day Treatment provides care for those with anorexia nervosa, bulimia nervosa, binge eating disorder, ARFID, OSFED and other eating disorders.
  • Monte Nido Houston Day Treatment is one of three Monte Nido & Affiliates programs in the state of Texas, complementing two residential programs also located near Houston, Monte Nido Houston for adults and Clementine Houston for adolescents.
  • Outcomes research demonstrates that clients who step-down from a Monte Nido & Affiliates residential program to a Monte Nido & Affiliates day treatment program have improved scores on eating disorder and depression measures at six-months post discharge when compared to those who do not step-down to a Monte Nido & Affiliates day treatment program.

From 2018 to 2022, Eating Disorder Claim Lines Increased 65 Percent Nationally as a Percentage of All Medical Claim Lines

Retrieved on: 
Mercoledì, Novembre 15, 2023
Binge eating disorder, Argyreia nervosa, Research, Policy, Telehealth, DSM-IV codes, ARFID, Database, Patient, Eating disorder, Male, Eating, FAIR, Diagnosis, Anorexia nervosa, Health, Numeral system, Bulimia nervosa, Female, Nursing, Dietary supplement

NEW YORK, Nov. 15, 2023 /PRNewswire/ -- From 2018 to 2022, eating disorder claim lines increased 65 percent nationally as a percentage of all medical claim lines.1 All eating disorders studied increased during this period, but at different rates: avoidant/restrictive food intake disorder (ARFID) by 305 percent,2 binge-eating disorder by 81 percent, anorexia nervosa (anorexia) by 73 percent and bulimia nervosa (bulimia) by 3 percent. These and other findings on eating disorders are reported in a FAIR Health white paper released today: Spotlight on Eating Disorders: An Analysis of Private Healthcare Claims.

Key Points: 
  • In 2022, binge-eating disorder was the eating disorder most commonly diagnosed without other accompanying eating disorders; 24.3 percent of all eating disorder patients were diagnosed with binge-eating disorder as the only eating disorder.
  • Bulimia, without any other eating disorder, accounted for 6.2 percent of all eating disorder patients, and ARFID for 5.3 percent.
  • The increase in eating disorder claim lines as a percentage of all medical claim lines varied by US census region from 2018 to 2022.
  • In 2022, eating disorder claim lines as a percentage of all medical claim lines varied by state.

Telehealth resources for eating disorders practitioners increases

Retrieved on: 
Giovedì, Ottobre 26, 2023
Telehealth, Insurance, Eating disorder, Education, HIPAA, Mortality, Argyreia nervosa, Disease, Research, International Association, Binge eating disorder, Internet, Disorder, Eating, Anorexia nervosa, EAPS, Patient, Doctor of Philosophy, Evidence-based practice, Nursing, MD

PEKIN, Ill., Oct. 26, 2023 /PRNewswire/ -- The International Association of Eating Disorders Professionals (iaedp™) is supporting telehealth practitioners and professionals in the eating disorder field. Telehealth saw a boom during the pandemic; the concept and practice were already in place well but is now a common occurrence. Rapidly, the iaedp Board of Directors saw the need to provide guidance and training on how to implement Telehealth in what is traditionally an in-person industry, how to address practitioners' concerns and how to share best practices across the industry.

Key Points: 
  • PEKIN, Ill., Oct. 26, 2023 /PRNewswire/ -- The International Association of Eating Disorders Professionals (iaedp™) is supporting telehealth practitioners and professionals in the eating disorder field.
  • Embracing telehealth practices decreases the time of intervention, increases patient accessibility, and provides a new path for care and treatment.
  • Continuing research provides insight into the effectiveness of telehealth treatment in eating disorders.
  • Through committed work from groups like the iaedp Telehealth Committee, professionals and practitioners can share ideas and recommendations while also keeping abreast of evidence-based practice.

Pioneers and Innovators in Psilocybin Treatments and How Big Pharma Wants in on the Game

Retrieved on: 
Giovedì, Ottobre 19, 2023
Post-traumatic stress disorder, Big Pharma, FDA, CAD, KAYS, Patent, Food, Oregon Health Authority, Therapy, Sacredness, COMPASS, DSM-IV codes, News, Pharma, FDT, US Foods, Research, Initial, OTCQB, Psilocybin, Yoga, Breakthrough therapy, Private placement, Good, Ōtsuka, Eating, Anorexia nervosa, Depression, OHA, Medication, Anxiety, Investment, Patient, Neuropsychiatry, TRD, Pulse, Mental health, Pharmaceutical industry, Nursing

As psilocybin and other alternative health innovators try to shape the future of mental health, Pharma and traditional healthcare investors are watching and waiting to get their share.

Key Points: 
  • As psilocybin and other alternative health innovators try to shape the future of mental health, Pharma and traditional healthcare investors are watching and waiting to get their share.
  • (OTCQB: KAYS) is the only U.S. public company engaged in securing an Oregon Health Authority ("OHA") license to open a psilocybin treatment center.
  • Kaya Holdings just announced that it has closed an additional round of bridge financing targeted to complete KAYS' planned psilocybin treatment center in Portland, Oregon.
  • Reporting on the Mindset Pharma deal, Psychedelicspotlight.com said , "Big Pharma has certainly taken note of the potential therapeutic benefits of psychedelics.

Eating Disorders Review Journal Expanding to Welcome New Editors and Comment Feature

Retrieved on: 
Martedì, Ottobre 24, 2023
Comment, National Association Medical Staff Services, Research, Vacuum, Social media, DSM-IV codes, Self-harm, Child and adolescent psychiatry, LDN, MD, Publication, News, Psychiatry, Argyreia nervosa, Doctor of Philosophy, International Association, Binge eating disorder, Trauma, Adolescence, Eating disorder, Nutrition, Eating, Anorexia nervosa, Psychopharmacology, RDN, Bentham Science Publishers, Diagnosis, Patient, Book, Dietary supplement, Nursing, Pediatrics, Child, Psychosomatic medicine

PEKIN, Ill., Oct. 24, 2023 /PRNewswire/ -- Eating Disorders Review, the renowned clinical journal and go-to source for eating disorder professionals about research, diagnosis, treatment and emerging practices, is expanding its scope and outreach to meet growing needs.

Key Points: 
  • The Review has added three new co-editors:
    Anne Marie O'Melia, MS, MD, CEDS-S, medical staff at Eating Recovery Center, Denver.
  • Dr. O'Melia has co-authored multiple articles and book chapters on eating disorders and served as a co-investigator for various clinical trials related to psychopharmacology in the treatment of eating disorders and mood disorders.
  • A founding member of the Academy for Eating Disorders, Leah has treated patients with eating disorders for more than 30 years.
  • It is just one of the International Association of Eating Disorders Professionals many resources for professionals and practitioners.

Everything Now: eating disorder recovery is treated with sensitivity and nuance in Netflix comedy drama

Retrieved on: 
Mercoledì, Ottobre 4, 2023
Learning, Male, Food, Gender identity, Argyreia nervosa, Snack, Life, Eating disorder, Noise, Friends, Culture, Mia, Woman, Anorexia nervosa, Human, Time, Risk, Eating, Quarterlife, Cheek, Research, Everything Now, Relative key, White, Mental health, Family, Female, Nursing, Dietary supplement, Toy, Netflix

Netflix couldn’t have chosen a more resonant title than Everything Now for their new comedy drama series.

Key Points: 
  • Netflix couldn’t have chosen a more resonant title than Everything Now for their new comedy drama series.
  • Some of these were impulsive – yet heartfelt – attempts to “catch up” on a life that had been passing me by.
  • This sense of things moving on while you have been trapped in the depths of an eating disorder is probably even more potent in the intensified temporal rhythms of teenage years.

The image of eating disorders

    • But eating disorders cut across ethnic boundaries.
    • Although there can never be any simple correlation between popular media representations of eating disorders and reality, they play a role in shaping wider understandings of eating problems.
    • Everything Now should be praised for recognising that it’s not just white, middle-class girls who experience eating disorders.

Nuanced representation

    • Everything Now is one of the first TV shows about eating disorders that did not make me cringe.
    • Switching between flashbacks of her time in the clinic and her present life at school and home, Mia’s voiceover communicates her struggles and anxieties.
    • As the camera pans over the nibbles and drinks at a party she asks: “How can they just eat and drink?

Representing recovery

    • I need to show them I’m better.
    • That I can be normal.” She is both present and not present – one of her peers yet so separate.
    • Everything Now depicts positive moments of recovery too, in ways that are touching and insightful.
    • Cut through the noise with a carefully curated selection of the latest releases, live events and exhibitions, straight to your inbox every fortnight, on Fridays.